PREP gene
Gilead Wins Groundbreaking FDA Approval for Twice-Yearly HIV Prevention Shot
Gilead; FDA approval; lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; long-acting injectable; WHO guidelines
FDA Approves Gilead’s Twice-Yearly HIV Prevention Shot
FDA approval; Gilead Sciences; Lenacapavir; Yeztugo; HIV prevention; twice-yearly injection; PrEP; public health
Gilead hops straight to Phase III with once-yearly HIV PrEP shot
PREP gene, formulations, once-yearly, Trial Phase
Gilead Sciences Prepares for Summer 2025 Launch of Long-Acting HIV Prevention Drug Lenacapavir
Gilead Sciences, lenacapavir, HIV prevention, PrEP, long-acting injectable, FDA approval, HIV sales, clinical trials, PURPOSE studies
Battle for HIV PrEP Market: Gilead’s Twice-Yearly Injection Challenges GSK’s Apretude
HIV prevention, PrEP, lenacapavir, Apretude, long-acting injectables, Gilead Sciences, GSK, ViiV Healthcare
HIV Prevention: A Proven Solution Eludes Many Due to Systemic Barriers
HIV Prevention, PrEP (Pre-Exposure Prophylaxis), Health Equity, Marginalized Communities, Stigma, Access to Healthcare
Gilead Expands Access to Long-Acting HIV PrEP with Licensing Deals for Generic Lenacapavir
Gilead Sciences, lenacapavir, HIV PrEP, generic licensing, long-acting HIV prevention, global health access
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Paving Way for Regulatory Filings
Gilead Sciences, Lenacapavir, HIV Prevention, Twice-Yearly PrEP, Regulatory Filings, PURPOSE 2 Trial
Gilead’s Twice-Yearly Lenacapavir Shows 96% HIV Risk Reduction, Eyes 2025 Launch for HIV Prevention
Lenacapavir, HIV Prevention, Twice-Yearly Injection, Gilead Sciences, PrEP, PURPOSE 1 and 2 Trials, Regulatory Filings, 2025 Launch
US Government Appeals Jury Decision in High-Stakes HIV PrEP Patent Battle Against Gilead
HIV, PrEP, Patent Battle, Gilead, Truvada, Descovy, US Government, Patent Litigation